We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals

99 hedge funds and large institutions have $348M invested in Vanda Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 44 increasing their positions, 19 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 19

102% more call options, than puts

Call options by funds: $40.3M | Put options by funds: $20M

86% more capital invested

Capital invested by funds: $187M → $348M (+$160M)

86% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 14

13% more funds holding

Funds holding: 8899 (+11)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
99
Holders Change
+11
Holders Change %
+12.5%
% of All Funds
3.21%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
26
Increased
44
Reduced
19
Closed
14
Calls
$40.3M
Puts
$20M
Net Calls
+$20.3M
Net Calls Change
+$8.83M
Name Holding Trade Value Shares
Change
Change in
Stake
MCM
51
Munder Capital Management
Michigan
$747K
Royal Bank of Canada
52
Royal Bank of Canada
Ontario, Canada
$734K +$272K +25,484 +61%
SCA
53
SAC Capital Advisors
Connecticut
$730K +$711K +66,500 New
Citadel Advisors
54
Citadel Advisors
Florida
$662K -$345K -32,294 -35%
California State Teachers Retirement System (CalSTRS)
55
California State Teachers Retirement System (CalSTRS)
California
$655K +$110K +10,323 +21%
DCM
56
Driehaus Capital Management
Illinois
$651K +$636K +59,486 New
Charles Schwab
57
Charles Schwab
California
$521K +$104K +9,700 +26%
AllianceBernstein
58
AllianceBernstein
Tennessee
$474K -$486K -45,521 -51%
TA
59
Teachers Advisors
New York
$469K +$78.3K +7,331 +21%
State Board of Administration of Florida Retirement System
60
State Board of Administration of Florida Retirement System
Florida
$460K
CCI
61
Columbus Circle Investors
$442K +$84.5K +7,907 +24%
Barclays
62
Barclays
United Kingdom
$442K +$371K +34,767 +369%
WMSA
63
Weiss Multi-Strategy Advisers
New York
$438K -$427K -40,000 -50%
FAM
64
Fortaleza Asset Management
Illinois
$430K +$420K +39,275 New
AQR Capital Management
65
AQR Capital Management
Connecticut
$385K +$216K +20,200 +136%
ProShare Advisors
66
ProShare Advisors
Maryland
$358K +$94.2K +8,818 +37%
LTFS
67
Ladenburg Thalmann Financial Services
Florida
$345K +$16K +1,500 +5%
CS
68
Credit Suisse
Switzerland
$324K -$14.6K -1,371 -4%
RhumbLine Advisers
69
RhumbLine Advisers
Massachusetts
$307K +$15.1K +1,412 +5%
AG
70
Algert Global
California
$293K -$1.49M -139,901 -84%
VOYA Investment Management
71
VOYA Investment Management
Georgia
$283K
MLICM
72
Metropolitan Life Insurance Company (MetLife)
New York
$277K
T. Rowe Price Associates
73
T. Rowe Price Associates
Maryland
$255K -$54.5K -5,100 -18%
SCM
74
Stevens Capital Management
Pennsylvania
$233K +$227K +21,274 New
NI
75
Numeric Investors
Massachusetts
$229K -$7.95M -743,647 -97%

VNDA Hedge Fund Activity: Q3 2013 in Review

99 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q3 2013, worth a combined $348M — up 86% from $187M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new VNDA positions and 14 closed out — a net gain of 12 holders — while 44 added to existing stakes and 19 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $25.3M. The largest seller was Consonance Capital Management, cutting an estimated $9.85M.

  • 99 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q3 2013, up from 88 in Q2 2013.
  • Funds reported $348M of Vanda Pharmaceuticals stock for Q3 2013, up 86% quarter-over-quarter.
  • 26 funds opened new Vanda Pharmaceuticals positions in Q3 2013 and 14 closed out, a net change of +12 holders.
  • The largest Vanda Pharmaceuticals buyer in Q3 2013 was Fidelity Investments, an estimated $25.3M added.
  • The largest Vanda Pharmaceuticals seller in Q3 2013 was Consonance Capital Management, an estimated $9.85M sold.

Based on aggregated 13F filings for Q3 2013.